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Abstract To determine the effects of antiepileptic drug
compounds on glioblastoma cellular growth, we exposed
glioblastoma cell lines to select antiepileptic drugs. The
effects of selected antiepileptic drugs on glioblastoma cells
were measured by MTT assay. For compounds showing
significant inhibition, cell cycle analysis was performed.
Statistical analysis was performed using SPSS. The
antiepileptic compounds selected for screening included
carbamazepine, ethosuximide, gabapentin, lamotrigine,
levetiracetam, magnesium sulfate, oxcarbazepine, pheny-
toin, primidone, tiagabine, topiramate, valproic acid, and
vigabatrin. Dexamethasone and temozolomide were used
as a negative and positive control respectively. Our results
showed temozolomide and oxcarbazepine significantly
inhibited glioblastoma cell growth and reached IC50 at
therapeutic concentrations. The other antiepileptic drugs
screened were unable to reach IC50 at therapeutic con-
centrations. The metabolites of oxcarbazepine were also
unable to reach IC50. Dexamethasone, ethosuximide,
levetiracetam, and vigabatrin showed some growth
enhancement though they did not reach statistical signifi-
cance. The growth enhancement effects of ethosuximide,
levetiracetam, and vigabatrin found in the study may
indicate that these compounds should not be used for
prophylaxis or short term treatment of epilepsy in
glioblastoma. While valproic acid and oxcarbazepine were
effective, the required dose of valproic acid was far above
that used for the treatment of epilepsy and the metabolites
of oxcarbazepine failed to reach significant growth inhi-
bition ruling out the use of oral oxcarbazepine or valproic
acid as monotherapy in glioblastoma. The possibility of
using these compounds as local treatment is a future area of
study.
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Introduction
Gliomas represent approximately 31 % of all primary brain
and central nervous system (CNS) tumors with glioblas-
toma multiforme (GBM) accounting for almost 17 % of all
tumors [1] Long term survivors of GBM are rare with a
median survival of less than 1 year being typical and a
5 year survival rate of less than 5 % [1–5].
Treatment of high grade gliomas typically includes
surgical excision followed by chemotherapy and symptom
management. GBM is treated with temozolomide (TMZ)
given concomitantly with radiation therapy (RT) to
increase efficacy and then continued as adjuvant treatment
for 6 to 12 months afterwards [4, 6–14].
Epileptic seizures are the presenting symptom of
intracranial lesions 30–50 % of the time [15, 16]. 10–30 %
of patients who are seizure free at diagnosis develop sei-
zures at some point throughout their disease progression [5,
16, 17] Patients that develop seizures are treated with anti-
epileptic drugs (AEDs) and some physicians may use
AEDs prophylactically to prevent possible seizure com-
plications after the diagnosis of cranial lesions or after
surgery. Since the pathophysiology behind these seizures is
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Valproic acid (VPA) is used for the treatment tumor
associated epilepsy (TAE) due to studies showing VPA to
have anticancer properties [4, 5, 9, 11, 12, 15–24]. In our
previous study to examine the correlation between the use
of VPA in patients diagnosed with GBM and patient sur-
vival, the results concluded that VPA, at serum concen-
trations used for the treatment of seizures (50–100 ug/ml),
may be beneficial and lead to a better prognosis in the
treatment of GBM when combined with total resection of
tumors and post-operative chemotherapy [25]. While some
studies examine VPA as a possible anti-cancer agent and
others examine the efficacy of AEDs for seizure reduction
in glioma and GBM, few look at the direct possible anti-
cancer effects of AEDs.
This cell culture study aims to address the following
points: 1) if VPA alone at the clinical therapeutic level
used for epilepsy treatment in patients has equivalent anti-
cancer effects in cell cultures, 2) at what concentration
does VPA alone demonstrate anti-cancer effects, and 3)
what other AEDs influence the growth of glioma/GBM
cells when used at the targeted therapeutic levels for sei-
zure control. Identifying the optimal use of VPA and
determining the effects of other AEDs on glioma/GBM
cells will allow for enhanced therapy which is important in
patients with GBM who have poor survival even when
given optimal therapy.
Materials and methods
Cell line selection and cell culture
Human glioma cell lines U-87 MG and T98G [American
type culture collection (ATCC), Manassas, VA] were used
in this study. The cell line U87 MG, used in multiple
studies, represents typical glioblastoma [26–28] The T98
cell line represents resistant glioblastoma due to TMZ
resistance [29] Cells were cultured in Eagle’s minimal
essential medium (EMEM) supplemented with 10 % Fetal
bovine serum (FBS), and 1 % antibiotic antimycotic
solution and placed in a standard humidified incubator at
37 C and 5 % CO2/95 % air atmosphere.
Drug compound selection
Drugs compounds were chosen based on the antiepileptic
drugs available on the Chang Gung Memorial Hospital
formulary. The compounds used are listed in Table 1.
Temozolomide acts as a positive control showing growth
inhibition. Dexamethasone (DEX) acts as a negative control
to show growth enhancement in GBM [30, 31] Licar-
bazepine (R-(-)-10-hydroxy- 10,11-dihydro- carba-
mazepine or monohydroxycarbamazepine (R-(-)-MHC))
and eslicarbazepine (S-(?)-10-hydroxy- 10,11-dihydro-
carbamazepine or monohydroxycarbamazepine (S-(?)-
MHC)), metabolites of the prodrug OXC, were added to the
compounds selected after preliminary data indicated that
OXC induced significant growth inhibition.
Reagents
EMEM powder and antibiotic/antimycotic solution were
obtained from Gibco, Grand Island, NY. FBS and phos-
phate buffered saline (PBS) were obtained from Hyclone
through Thermo Scientific. Dimethyl sulfoxide (DMSO),
ethanol (99 %) (EtOH), TMZ, DEX, VPA, carbamazepine
(CBZ), ethosuximide (ESX), gabapentin (GBP), lamotrig-
ine (LTG), levetiracetam (LEV), magnesium sulfate
(MgSO4), oxcarbazepine (OXC), phenytoin (5, 5
diphenylhydantoin) (PHT), primidone (PRM), tiagabine
(TGB), topiramate (TPM), and vigabatrin (VBT) were
obtained from Sigma-Aldrich, St. Louis, MO. R-(-)-MHC
and S-(?)-MHC were obtained from Santa Cruz, Dallas,
TX.
Dose determination
The drug concentration ranges chosen for this study were
taken from estimated drug plasma levels reported to be
found in patients with adjustments for protein binding as
needed [32–35]. The range was based on the minimum
reported effective plasma level and the maximum reported
level found in patients [35–38]. Toxic plasma levels were
determined from Micromedex and other reports [35–38].
The drug concentration range for VPA was extended to
toxic levels to ensure that IC50 for VPA would be obtained
due to reports of VPA as an anti-cancer agent (Table 1).
Experimental procedure
Cells were collected and seeded in 24-well plates at a
density of 1 9 104 cells/well (U-87 MG) and 5 9 103 -
cells/well (T98G) after optimization at the beginning of the
experiments. After 24 h, drug was added to each well to
reach the dosing concentrations listed in Table 1. The
treated cells were incubated for 72 h after which cell via-
bility was assessed.
Cytotoxicity/cell viability assay
Cytotoxicity/cell viability analysis was performed using
the 3-(4, 5-dimethylthylthiazol-2-yl)-2, 5-diphenyltetra-
zolium bromide (MTT) method. 50 ll of MTT tetrazolium
salt (Sigma) dissolved in PBS at a concentration of 5 mg/
ml was added to each well at 70 h post treatment and
incubated for 2 h. The medium was then aspirated from
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each well and 200 ll of DMSO was added to dissolve the
formazan crystals. 150 ll of the resulting solution was
transferred to a 96-well plate and the absorbance of each
well was obtained using a Tecan infinite M200 Pro plate
reader at a wavelength of 570 nm. Each experiment was
replicated multiple times with similar results.
Cell cycle analysis
If growth inhibition reached 50 % (IC50), cell cycle anal-
ysis was performed. Cells were trypsinized and harvested
and fixed in 70 % ethanol for at least 30 min at 4 C. After
the removal of the alcoholic fixative, they were stained
with a solution containing 50 lg/ml Propidium Iodide (PI)
and 100 lg/ml RNase A (Sigma) for approximately 30 min
at room temperature while being protected from light.
Samples were then measured using flow cytometry
(FACScans, Becton–Dickinson). Ten thousand events per
sample were acquired and the data was analyzed using Cell
Quest software (Becton–Dickinson).
Statistical analysis
The data were expressed as mean ± standard deviation
(SD). Statistical analysis was performed with Statistical
Product and Service Solutions (SPSS) using analysis of
variance (ANOVA). The criterion for statistical signifi-
cance was taken as p\ 0.05.
Results
Cytotoxicity/cell viability
Overall growth inhibition for all compounds and cell lines
are shown in Fig. 1. Figure 2 depicts the maximum growth
Table 1 List of antiepileptic compounds used in this study and associated abbreviations, therapeutic plasma levels for epilepsy treatment,








Temozolomide TMZ 4–11 Determined by
myelosupression/
hepatotoxicity
0.04, 0.4, 4, 10,
20, 40
Dexamethasone DEX 2.6–18 Rat LD50 3 gm/kg 0.008, 0.08, 0.8,
16, 40
Valproic acid VPA 50–150 450–850 lg/ml 10, 100, 250, 500,
1000
Carbamazepine CBZ 4–12 18–42.8 lg/ml 1, 2, 4, 8, 16
Ethosuximide ESX 40–160 [150 lg/ml 10, 20, 40, 80,
160
Gabapentin GBP 2–8.6 40–100 g 0.2, 2, 10, 20
Lamotrigine LTG 0.5–5.4 13–62.4 lg/ml 0.2, 2, 10, 20
Levetiracetam LEV 6.85–72 60–400 lg/ml 5, 10, 20, 40, 80









3–35 30–40 lg/ml 12.5, 25, 75
Eslicarbazepine (S-(?)-10-hydroxy- 10,11-dihydro-
carbamazepine/monohydroxycarbamazepine)
S-(?)-MHC 3–35 30–40 lg/ml 12.5, 25, 75
Phenytoin PHT 10–20 20–40 lg/ml 0.04, 0.4, 4, 20,
40
Primidone PRM 5–12 40–80 lg/ml 0.2, 1, 5, 12.5, 25
Tiagabine TGB 0.04–0.55 0.7–4.6 lg/ml 0.0008, 0.008,
0.08, 0.8
Topiramate TPM 2–19 9.4–170 lg/ml 0.2, 2, 10, 20
Vigabatrin VBT 5.3 60 g 0.04, 0.4, 4, 20,
40
J Neurooncol (2016) 127:445–453 447
123
Fig. 1 Growth inhibition for all
compounds and cell lines.
a Growth inhibition for TMZ,
VPA, and OXC, the three
compounds that attained over
50 % growth inhibition.
b Growth inhibition for the
OXC metabolites R-(-MHC
and S-(?)-MHC. c Growth
inhibition and enhancement for
DEX, VBT, LEV, and ESX, the
four compounds that displayed
both growth inhibition and
growth enhancement. d Growth
inhibition for MgSO4, CBZ,
OHT, TPM, LTG, GBP, PRM,
and TGB, the compounds that
showed growth inhibition, but
did not attain over 50 % growth
inhibition
448 J Neurooncol (2016) 127:445–453
123
inhibition reached by each compound and can be separated
into control compounds, non-effective compounds, and
effective compounds, with effective compounds consisting
of those that reached half maximal inhibitory concentration
(IC50) as shown in Table 2.
Control group
For TMZ, the growth inhibition for the T98G cell line
(means and SDs) for each concentration was 17.6 ± 1.5 %
(0.04 lg/ml), 19.4 ± 3.1 % (0.4 lg/ml), 19.2 ± 0.7 %
Fig. 2 a The 17 compounds
ordered according to maximum
percent of growth inhibition
after treatment using the T98
cell line with a minimum of
three replicates. b The 17
compounds ordered according
to maximum percent of growth
inhibition after treatment using
the U87 cell line with a
minimum of three replicates
Table 2 IC50 of the effective compounds and compound metabolites
screened with the U87 and T98 cell lines
IC50 drug concentrations
Drug name U87 lg/ml T98
AED Oxcarbazepine 12.35 9.45 lg/ml
AED Valproic acid 808.82 652.78 lg/ml
Positive CTL Temozolomide 3.4 *
* IC50 was not reached in the T98 cell line using the highest drug
concentration (40 lg/ml) of TMZ
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(4 lg/ml), 18.9 ± 9.1 % (10 lg/ml), 29.3 ± 6.8 %
(20 lg/ml), and 23.8 ± 1.4 % (40 lg/ml). For U-87 MG it
was 21.8 ± 4.8 % (0.04 lg/ml), 29.0 ± 5.5 % (0.4 lg/
ml), 51.6 ± 3.1 % (4 lg/ml), 71.8 ± 2.2 % (10 lg/ml),
70.0 ± 1.4 % (20 lg/ml), and 58.2 ± 0.8 % (40 lg/ml).
The T98 cell line was unable to reach IC50 at the con-
centrations used and only the 20 lg/ml concentration
showed statistically significant growth inhibition (p
value = 0.01). For U87, statistical significance was found
at all concentrations (p values of 0.012 (0.4 lg/ml) and
\0.001 (4,10, 20, 40 lg/ml)) and IC50 was calculated to be
3.4 lg/ml.
For DEX, the growth inhibition for the T98G cell line
for each concentration was -0.3 ± 7.5 % (0.008 lg/ml),
5.6 ± 6.0 % (0.08 lg/ml), 4.8 ± 5.8 % (0.8 lg/ml), 3.5 ±
5.0 % (16 lg/ml), and 2.7 ± 6.5 % (40 lg/ml). For U-87
MG it was -1.7 ± 5.1 % (0.008 lg/ml), 5.3 ± 2.4 %
(0.08 lg/ml), 3.5 ± 7.4 % (0.8 lg/ml), 0.3 ± 9.2 %
(16 lg/ml), and -4.2 ± 9.6 % (40 lg/ml). While some
concentrations resulted in a negative growth inhibition, it
did not reach statistical significance.
Non-effective group
The growth inhibition for R-(-)-MHC in the T98G cell
line (means and SDs) for each concentration was 1.3 ±
1.2 % (13 lg/ml), 6.5 ± 5.3 % (25 lg/ml), and 8.9 ±
6.7 % (76 lg/ml). For U-87 MG it was 24.0 ± 6.8 %
(13 lg/ml), 26.2 ± 11.7 % (25 lg/ml), and 34.9 ± 8.0 %
(76 lg/ml). The growth inhibition for S-(?)-MHC in the
T98G cell line for each concentration was 1.2 ± 0.4 %
(13 lg/ml), 4.2 ± 3.6 % (25 lg/ml), and 7.6 ± 5.6 %
(76 lg/ml). For U-87 MG it was 11.6 ± 5.2 % (13 lg/ml),
13.0 ± 6.0 % (25 lg/ml), and 19.3 ± 0.7 % (76 lg/ml).
LTG, MgSO4, and PHT showed statistically significant
growth inhibition in both cell lines, however, they did not
reach IC50. Exposure to CBZ, ESX, and GBP resulted in
statistically significant growth inhibition in the T98G cell
line only, but also failed to reach IC50. The other
antiepileptics, LEV, PRM, TGB, TPM, and VBT, used in
this study failed to reach statistically significant growth
inhibition. While VBT, LEV, ESX, and DEX did show
some growth enhancement in the U87 and T98 cell lines, it
was not statistically significant level.
Effective group
For VPA, the growth inhibition for the T98G cell line
(means and SDs) for each concentration was 5.2 ± 4.1 %
(10 lg/ml), 13.9 ± 4.8 % (100 lg/ml), 26.0 ± 5.3 %
(250 lg/ml), 42.3 ± 11.7 % (500 lg/ml), and 67.5 ±
3.7 % (1000 lg/ml). For U-87 MG it was 0.7 ± 3.4 %
(10 lg/ml), 8.4 ± 1.8 % (100 lg/ml), 21.7 ± 3.4 %
(250 lg/ml), 41.6 ± 2.3 % (500 lg/ml), and
55.2 ± 3.3 % (1000 lg/ml). Statistically significant dif-
ferences were found at the 100, 250, 500, and 1000 lg/ml
concentrations for the U87 cell lines (p values of\0.001)
and at the 250, 500, and 1000 lg/ml concentrations for the
T98 cell lines (p values of \0.001). IC50 was found at
concentrations [652.78 lg/ml for the T98 cell line and
[808.82 lg/ml for the U87 cell line.
For OXC, the growth inhibition for the T98G cell line
for each concentration was 17.7 ± 4.1 % (2.5 lg/ml),
21.1 ± 3.6 % (5 lg/ml), 53.6 ± 14.2 % (10 lg/ml),
82.2 ± 2.3 % (20 lg/ml), and 85.0 ± 2.3 % (40 lg/ml).
For U-87 MG it was 8.0 ± 11.8 % (2.5 lg/ml),
11.7 ± 5.3 % (5 lg/ml), 42.1 ± 17.6 % (10 lg/ml),
75.7 ± 4.7 % (20 lg/ml), and 89.0 ± 1.8 % (40 lg/ml).
Statistically significant differences were found at the 10,
20, and 40 lg/ml concentrations for the U87 and T98 cell
lines (p values of\0.001). IC50 was found at concentrations
[9.45 lg/ml for the T98 cell line and[12.35 lg/ml for
the U87 cell line.
Overview of cytotoxicity/cell viability
As seen in Fig. 2, the only VPA and OXC in the T98 cell
line and VPA, TMZ, and OXC in the U87 cell line reached
over 50 % growth inhibition. In the T98 cell line, no
compounds showed growth enhancement, 6 compounds
(R-(-)-MHC, S-(?)-MHC, DEX, LEV, ESX, TGB)
showed less than 10 % growth inhibition, and 9 com-
pounds (VBT, PRM, GBP, TPM, LTG, PHT, TMZ, CBZ,
MgSO4) showed 10–35 % growth inhibition. In the U87
cell line, 2 compounds showed growth enhancement (VBT
7 %, LEV 3 %), 4 compounds (ESX, DEX, TGB, PRM)
showed less than 10 % growth inhibition, and 8 com-
pounds (LGT, GBP, PHT, MgSO4, TPM, CBZ, R-(-)-
MHC, S-(?)-MHC) showed 10–35 % growth inhibition.
ESX and DEX also showed slight growth enhancement at
high drug concentrations.
Cell cycle analysis
Cell cycle analysis was performed for TMZ, OXC, and
VPA. The drug concentrations used for cell cycle analysis
were 300 lM for TMZ (*60 lg/ml) and OXC (*80 lg/
ml), and 10 mM for VPA (*1500 lg/ml). Flow cytometry
was performed and the results given in Fig. 3.
TMZ was shown to have minimal effect on the T98 cell
line, but induced G2/M arrest in the U87 cell line and
increased SubG1 indicating apoptosis. OXC was shown to
have greatly increased the SubG1 population in both T98
(91.4 %) and U87 (77.1 %). VPA was also shown to
greatly increase the SubG1 population in T98 (88.1 %).
Preliminary experiments using lower concentrations and
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shorter incubation times for VPA and OXC indicate a
possibility of G2/M arrest at shorter incubation times and
similar patterns in lower concentrations as long as IC50 is
reached.
Discussion
In this study, we investigated three main areas, the effect of
VPA alone on cancer cell growth, the concentration of
VPA needed to affect cell growth, and the effects of var-
ious AEDs on cell growth.
The effects of valproic acid
Multiple studies have shown that the use of VPA in GBM
results in cell growth inhibition in both the U-87 MG and
the T98G cell lines. The drug concentration doses in these
studies ranged from *35 to *1500 lg/ml. The data from
these studies indicated that at *500 lg/ml, a significant
level of growth inhibition, approximately 40–60 %, was
reached [39–41].
While the results of our study did find significant growth
inhibition and apoptosis caused by VPA alone, the IC50
was found at concentrations that would be considered toxic
when used in patients. The IC50 calculated for both cell
lines were higher than that reported by others and far
exceed the normal serum concentrations levels for the
treatment of seizures (50–100 ug/ml). At therapeutic con-
centrations, VPA alone showed less than 20 % growth
inhibition. This indicates that VPA alone does not provide
significant anti-cancer effects and the effects seen in our
previous study on VPA in patients may be influenced by
the fact that VPA was used in combination with TMZ, the
chemotherapy of choice, or possibly radiation therapy
(RT).
The effects of other AEDs
Of these other compounds used in this study, only OXC
was shown to have significant inhibitory effects at what
would be considered therapeutic levels for the treatment of
epilepsy. The results for OXC showed that OXC was
effective in inhibiting cell growth, was able to attain IC50,
and induced possible G2M arrest and apoptosis. This
information is similar to another study that also showed
that OXC had possible anti-cancer effects in other cell lines
though the concentrations used in that study far exceeded
what would be considered therapeutic for epilepsy [42].
Further study is required to determine the exact mechanism
behind the inhibitory effects of OXC. Due to the fact that
OXC is a prodrug, the metabolites (R-(-)-MHC and
S-(?)-MHC were also assessed for cell growth inhibition.
The metabolites did not reach 50 % growth inhibition even
at a concentration double the maximum accepted thera-
peutic plasma level for OXC metabolites. This discovery
indicates that since OXC is quickly metabolized into
R-(-)-MHC and S-(?)-MHC when OXC is taken orally,
OXC may need a local delivery system to provide anti-
cancer effects and bypass metabolism.
None of the other epileptics used in this study reached
IC50. MgSO4, PHT, CBZ, LTG, GBP, PRM, TGB and
TPM showed overall growth inhibition in both cell lines.
Even though CBZ and OXC have similar chemical struc-
tures, CBZ did not reach IC50 in our study and another
study has shown that they are distinctly different drugs in
their mode of action, metabolism, efficacy, and tolerability
[43]. DEX and ESX showed slight growth inhibition in the
T98 cell line, but growth enhancement at higher concen-
trations in the U87 cell line. LEV and VBT showed growth
inhibition in the T98 cell line and growth enhancement in
the U87 cell line at all concentrations. While the growth
enhancement effects of ESX, LEV, and VBT failed to
reach significance, the possible effects of these compounds
should be taken under consideration when choosing
epileptic therapy in patients with GBM.
Impact on clinical practice
While the survey of antiepileptic compounds was per-
formed on glioblastoma cell lines and not in actual patients,
there are still some aspects of this study that can be of
benefit when considering the use of antiepileptics in the
treatment of GBM patients.
While toxic doses of valproic acid are required to reach
significant growth inhibition in this study, our previous
Fig. 3 Effect of TMZ, OXC, and VPA on cell cycle in two glioma
cell lines
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study did find merit in the use of VPA in conjunction with
standard therapy [25]. This finding also matches other
studies that have found that VPA can be of benefit in some
cancer patients though not in all cancer types [44–47].
While none of the current studies found that VPA alone
improved outlook for cancer patients, VPA in conjunction
with other therapies was found to possibly have benefit in
some cancer types [25, 44–47]. While oral VPA
monotherapy is impractical in GBM, local treatment using
a wafer implanted after surgery may allow for higher local
saturation to reach the needed concentration.
For oxcarbazepine, no clinical studies in patients have
been reported. While oxcarbazepine did reach significant
growth inhibition, which matches the information found by
another study, it is a prodrug that is quickly metabolized
[42]. While the parent drug, oxcarbazepine, has significant
inhibitory effects, the metabolites of oxcarbazepine, licar-
bazepine and eslicarbazepine, did not reach significant
growth inhibition indicating that orally given oxcar-
bazepine may not be clinically useful in treating GBM. The
effectiveness of oxcarbazepine does indicate that it may be
useful as a local treatment in the form of wafer implanted
post surgery. Additional studies will be performed to
explore this possibility.
Another important aspect of this study is the finding that
some antiepileptics may have slight growth enhancement
effects in GBM. While the growth enhancement was not
significant, it is still important to note that the antiepileptics
studied fell into two basic groups. The first group, con-
sisting of VPA, OXC, R-(-)-MHC, S-(?)-MHC, MgSO4,
PHT, CBZ, LTG, GBP, PRM, TGB and TPM, show
growth inhibition of GBM cells indicating that the use of
these compounds for the treatment of epilepsy in GBM
patients is safe and has no negative impact on GBM
patients. The second group, consisting of ESX, LEV, and
VBT, however, showed minor growth enhancement. This
finding, while not reaching significance, does call into
question if these compounds should be avoided when
deciding on prophylactic antiepileptic therapy or choosing
antiepileptic therapy for newly diagnosed patients with
GBM. With the multitude of options available for
antiepileptic treatment, it may be useful to consider
choosing antiepileptic compounds that demonstrate no
growth enhancement at all over those that showed even
slight growth enhancement.
Conclusion
Our results showed that TMZ, valproic acid, and oxcar-
bazepine significantly inhibited glioblastoma cell growth
and that VPA and OXC may induce apoptosis or G2M
arrest in glioblastoma cell lines. It was also demonstrated
that OXC metabolites did not impact cell growth, thera-
peutic levels of VPA were not effective, and that toxic
levels of VPA are needed to impact cell growth. These
findings indicate that while VPA and OXC may not be
useful as anti-cancer therapy when used as treatment for
epilepsy, it is possible that both compounds may have
efficacy when used as local treatment in the form of a wafer
or local implant to bypass the issues of toxicity and
metabolism. The other antiepileptic drugs screened did not
show significant growth inhibition or enhancement, though
the compounds that enhance cell growth may need further
consideration before use in GBM patients. Future studies
are needed to examine the effectiveness of AEDs when
given in combination with standard GBM therapy, to define
the mechanism behind OXC’s effectiveness, and to explore
the possibility of using VPA or OXC as local treatment.
Furthering our understanding of AEDs used in the treat-
ment of GBM patients can lead to the development of
better clinical therapy guidelines.
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